Our findings suggest that targeted therapy would be beneficial for patients with epithelioid glioblastoma harboring BRAF V600E mutation, and that establishment of cell lines and xenografts would be useful for predicting the effectiveness and overcoming the resistance mechanisms of precision-based treatments. Here, BRAF is linked to glioblastoma.